What are the novel cancer therapies ?
In the last 10 years, major advances in understanding how cancers behave have given doctors the opportunity to select treatments based on the presence of specific biomarkers and to personalize a treatment plan for each patient. Tumor profiling can help not only to increase chances of survival, but also to avoid unnecessary treatments and potential toxicity. While chemotherapies act on all rapidly dividing cells, normal and tumor, find out how these new therapies work to treat cancer patients.
- Targeted therapies neutralize the tumor by acting on specific targets (changes in the cancer cells) involved in its spread or causing its growth. They act only on the cells containing these targets, so mostly on the cancer cells.
- Hormone therapy uses drugs to block or lower the hormone level in the body, in order to slow down or stop the growth of some cancers, for example, for hormone-receptor-positive breast cancers (HR+) and some prostate cancers.
- Immunotherapy is a way to stimulate the patient’s immune system to destroy their cancer cells. Some drugs recognize specific molecules on the surface of cancer cells while others can bind to the immune cells to help them kill cancer cells. Read how OncoDNA is helping oncologists selecting immunotherapy for their patients.
- Proton therapy is considered to be the most advanced form of radiation therapy. It is particularly appropriate in situations where treatment options are limited and conventional radiotherapy presents unacceptable risks to patients (for example cancers of the eye and brain, head and neck, prostate, liver, lung and breast and pediatric cancers).
Why choose OncoDNA ?
Based solely on tumor DNA analysis, we are able to find a targeted therapy for approximately 25% of patients. But since we also look at other characteristics of the cells, we can identify potential good responders for immunotherapy or evaluate which chemotherapy options have more chances of succeeding. We’ve been able to help many patients with our solutions.
What about reimbursement or financing these tests?
Our tests are currently reimbursed in a growing number of countries.
• In the United Kingdom
OncoSTRAT&GO is reimbursed for patients insured by BUPA Global Insurance, using code 7331B and also many other insurers.
• In Belgium
the Liberal Mutuality Namur Hainaut are financing partially the test:
• In Luxemburg,
The National Health Institute support the cost of OncoDEEP
Read the PRESS RELEASE
like Spain, Chile and South Africa, also cover the cost of our test, either totally or partially. Don’t hesitate to contact us for more information.
Financing the tests with “La Cagnotte de Proches”
OncoDNA signed a partnership with “La Cagnotte des Proches” a specialist in health crowdfunding.
This exclusive partnership has been approved for Belgium and France to help patients to finance the molecular profiling tests.
La Cagnotte Des Proches is an online crowdfunding that specializes in fundraising to help patients finance their healthcare costs. Their moto: patients must no longer suffer the financial consequences of an illness, especially when their survival or well-being is at stake.
More information: http://lacagnottedesproches.com/oncodna
From that time, my whole life changed, I had new hope. I saw my life completely differently, I wanted to live, I wanted to fight this cancer. And why shouldn't I be cured ?
I have 100% faith again and I think it's thanks to all this: Dr Mouysset, the journey I've been on personally, what you do, the innovations you set up !
I've recommended lots of people in the same situation as me to have these tests done, to find a way out of the situation !